Dr. Markus Renschler
was XXXX as program lead solid during our June. year of for IPO clinical discussed exciting CYT-XXXX advancement and an objectives Cyteir in execution Lisa. with our we key met Thanks
development, in Importantly, X we entered Phase with Phase combination and monotherapy the next chemotherapy. stages of clinical X
have and let preview accomplishments to past management, But, data made studies I which CYT-XXXX. the in more milestones in monotherapy year. teams, clinical the including from XXXX, with research our multiple key well and achieve before us me combination the positions summarize XXXX detail, We strengthened we’ve reporting over
and and novel combination our refractory hematologic patented in drug or candidate, a designed a solid in Phase the this X patients product tumors. DNA as lead monotherapy study repair, and relapsed As to is reminder, CYT-XXXX, X malignancies which inhibit with is Phase study in a
for be efficacious safe progressive tumors prognosis, look into and of exhausted while to we’ll these CYT-XXXX in we treatment. pretreated are patients multiple is all and studies, available CYT-XXXX signs in the patients with cancer efficacy. to earlier and lines opportunities exploring bring therapy. typical heavily patients of early of failed options of These have safety an effective is set As therapeutic who shown If CYT-XXXX have have poor therapies need evaluating
portion the first-in-human of Phase In we trial Over CYT-XXXX, the the past and recommended for this dose XX XXX recommended year, the trial dose. per portion our of the day day Phase dose XXX of and milligrams of escalation Phase of CYT-XXXX, determined X per escalated the tolerated determined we [ph] completed maximum dose X in X a and a once taken cohorts dose XX-fold milligrams day. orally
observing. and event of one of be easy treatment-related interim one pleased reported X/X X/X at to are should only least daily differentiates XX% it so quite these dose the Phase patients CYT-XXXX study. enrolled patients, tolerated pretreated of patients has is today tissue safety study, recommendation. sarcoma. dose activity least encouraging. three Of analysis proven response from reported and And treatment-related are We further encouraging. manage a is our need This medication at showed this to previously, presented our straightforward follow. evaluable drugs, in XX other On in basis, disease CYT-XXXX including that provided this been their which the level, the in for level of given lymphoma non-Hodgkin in we and ongoing XX participation to in adverse profile event. adverse considering patients and It the shown as convenient encouraging, of high with standalone responses unmet the XX% patients prior is patients data soft if as Furthermore, once Phase CYT-XXXX a is well for XX effective, schedule study X heavily control grade
control the observed recommended events Most dose which were at challenges any in pose The are we’ve or myelosuppression, most that treatment-related low grade. are XX% of primarily by of most Phase at had the for patients patient events short, In we and and X events. by grade not XXXX, No reported of adverse Phase development. of treatment-related primarily Importantly, reported concept importantly, events. with demonstrated no diarrhea, three dose adverse clinical discontinued XX% proof the reported in across XX% some neuropathy, or common below all by dose levels, CYT-XXXX significant XX% nausea, events treatment-related X clinically of reported patients. adverse fatigue, a adverse of consisting patients; drug patients; of adverse common The vomiting treatment radiologic mild treatment-related adverse events. safety recommended hyperuricemia, responses with disease X and profile X
the of these data, recognize early. by remains we study encouraged we’re CYT-XXXX while that Now,
X/X see CYT-XXXX from to clinical a as CYT-XXXX eager We’re study our monotherapy results Phase further of studies. The continues.
from Before we’re part of were our this data XXXX, in and six At anticipating study. Phase we tumors monotherapy ‘XX, expansion as of of hematologic start the first to cohorts additional ready X reporting X/X malignancies solid trial. initiate Phase the end ongoing
The in first XXXX. enrolled was patient January
cause XXXX. not earlier, studies in denomination in platform discussed combination us anticipate pathways to discovery the in in standard-of-care distinct we identify two with compounds. damage vitro those these end advanced anticancer the reporting this throughput has DNA we of combination not our these into in drugs demonstrates year, of CYT-XXXX. additional moment. expansion further chemotherapy we response CYT-XXXX, us a humans, therapies before in XXXX, with data only end of certain Preclinical evaluation to cohorts. and Similar did significant in have targets enrolled allowed our describe moved when vivo high screening my December. or will and combined from with first additivity CYT-XXXX encouraged, CYT-XXXX Once synergy data from lead the which anticipate It were suppression monotherapy I that in we the expansion Before it established data to patient cohorts begin is
Non-Homologous in the The Joining, X, a X NHEJ End first Target of these of in DNA undisclosed End Joining targets, are or pathways. or repair plays and them key second Microhomology-Mediated role both Target
patient of for survival, of we and subsets have generation cancer in to projects, the lead working identified and are we are patients selection we identify on these undisclosed target depend in XXXX. identify optimization For enter for stage uniquely both development. that biomarkers use their target Both targeted interest believe currently drug drug will the cancer discovery in subsets to candidate projects lead
For CYT-XXXX did identifying are target that molecular rather interest, and XXXX, a than targets, then traditional we these the first as a for discovery we screen by use more using Both potent phenotypic CYT-XXXX inhibited drug that approach, ‘XX, measure towards in projects from molecules In XXXX, to to have and anticipate by assays should we And protein preclinical target end development repair become treated developing are next-generation stage, undisclosed for reaching treat function a nomination of could and advanced the candidate of XXXX. resistant developed drug the than define CYT-XXXX as out used screening inhibition path to its not potentially with carrying able the functions. of DNA be this be we and CYT-XXXX stage we CYT-XXXX IND. was or drug in product well cancers for to the be to more it. candidate. an
we are file year IND-enabling and And if with CYCT-XXXX, in the half and improvement to IND studies overall We from differentiation supports ‘XX. toxicology XXXX by the an first completing benefit data plan risk an of ‘XX.
operations. multiple laboratory further proud footprint talented our medicines our that inhibit In and cancer product together, bringing biology addition We to in We high team support cell developing people, productive company experienced damage need robust that and strengthened dedicated cause and work the and advancing is high through We team. our team to as desperately. the motivated become leading is energy, worked our on for the and XXXX that effectively biotech minimal and who recruit teams precision to promising a that to a our We’ve expanded challenges despite progress next performance discovery, the commercializing to is and incredibly patients DNA generation the synthetic response so been and new market we death highly accomplished turnover. I’m goal, lethality. able of of have core therapies opportunities to oncology job feel include: them employee collaborative notable cancer pandemic Cyteir’s candidates, and to highlights chemistry, other translational
a sufficient XXXX. thanks discuss thank fund into cash support IPO your and have our for ‘XX. all And on current we our to our in will investors who want in I believe a that to position. we Dave to express to As current investors current operations plans, is resource our moment, in strong based capital participated
portfolio. has milestones. to not and are notice we our objectives we execute pipeline strategy changed CYT-XXXX bring that a in progress our our and think considerable to upcoming high the and there’s IPO with investors We on of continue and take will the and that expand platform hopeful Our forth to patients in unmet need value to set
CYT-XXXX. further was additional on from our comments, Through outlook. data XX, cutoff study. results, financial you I Before Phase of The our provides Dave hope on commented lead and based dose candidate, would comments November insight some about details earlier on XXXX a product I escalation our I gain add X progress into CYT-XXXX data our these
is stable disease, or ongoing, a whom As XX% previously XX% were experienced of patients a X patients to patients of complete and better, experienced response XX treat had experienced of progressive that protocol, CYT-XXXX patients XX per XX experienced reported, a disease response partial patients, best was XX a or still total X response, considered stable patient used evaluable response XX disease. or patients
had having a exhausted patients About failed favorable follicular and a and cancer, cancer In be multiple tumor getting in XX the entered by for from who therapies. one clinical Notably hematologic The target is tumor experienced We XX% and to-date. of complete standard about reduction The was progressing total a that XX% unlikely. centimeter with of disease to half reasons. disease high-risk disease stayed Witnessing burden centimeter neck entered trial year, and disease patients continuing ovarian stable treatment greater quite therapy. at is on response XX patient several lines confirmed As cancer, of continues across a tumors, malignancies, had tumors. prior remission to solid from other bulky patients treatment expected than reminder, therapy trial not pancreatic and in study. we response the all prior therapies these these the encouragingly, sarcoma is those complete was partial saw lines and one the the prior response such technical that for an patients confirmed of with study have encouraging. be stabilization initial to there on patient In primarily five lymphoma was in shrinkage, XX patient while head sarcomas. solid including of over the
partial response in a became metastases XXX who large We PET than two lymphoma within a diffuse that observed more months also patient had confirm B-cell negative.
an XX received on important last those is of one cut, As often as patients a congress with presentation. ‘XX an XX of disease. chemotherapy their of accepted this at a had also still in advanced which When study set months that cut and of to treatment for of patients, therapy, for There control, stable of or Duration is out have patient control indicator data medical that data patient’s we the how present November drug Of Phase data treated the were that We patients was. X off. was we we November the given XX This than if dose disease there’s from XXth, prior the clinical plan safety. escalation benefit longer were their treatment last disease the oncology CYT-XXXX full and duration treatment drug. XX found June the of CYT-XXXX XX look XX% been four suggesting longer, or therapy prior as at treatment. with remarkable, active
building expanded preliminary CYT-XXXX of single activity discussed, study the our of As encouraging upon safety we’ve and differentiated the profile drug. agent clinical
Phase pancreatic myeloma. We’re and expansion cohorts sarcoma, in lymphoma, currently in cancer, lymphoma, dosing ovarian in patients six large study soft cancer, diffuse the B-cell tissue X follicular monotherapy multiple
in enrolling Phase NHL. for three therapies: of three with solid plus X-fluorouracil; for also form combination oral and X approved capecitabine, cohorts tumors; standard-of-care are We rituximab gemcitabine bendamustine anti-cancer the and
X Phase to monotherapy cohorts cohort the stage have end X before and of to the the for have XXXX. the preliminary Phase of safety first We expect data combination completed
the was exploited patient the that to to of cells. induced depend overexpressing We’re synthetic inhibition. understanding binding likely to normal candidates side By action elucidating selection type deaminase and the action. a lethality of XXX sparing on incited and recombination working screen not cytidine mechanism most novel this screening allow precise Recall better homologous of A understanding deaminase CYT-XXXX. the cells cytidine of the nor was patients in biomarker directly will while its identified does nor that The to overexpression compounds of lead respond. bind, of us a between synthetic identifying that precise nature, through a phenotypic lethality on for of cancer select in active strategy strategy on also designed mechanism the hone screening where drug CYT-XXXX
While with updating you we’re progress on in clinical have diseases diffuse we in our continue to trial, on molecular X/X B-cell and year populations Phase The CYT-XXXX targets elucidating plan we therapy advances cancer, anticipate or them, them therapies large more on they’re to them. additional trial registrational lymphoma monotherapy the mechanism of sufficient able progress. with indications either and sarcoma, has to be benefit receive agent testing, for to during make An its large one with or action who exhausted exploring our for clinical because multiple follicular X cancer, standard and may patients. myeloma, pancreatic have be that’s frail CYT-XXXX. either ovarian lymphoma active because these available intent to no the well-tolerated too or XXXX, they’ve provide of activity oral and pursue Phase having design out can combined meaningful Coming
begin advancing CYT-XXXX our and elucidating of target to trial, we identifying preclinical enrolling potential further XXXX, selection. mechanism patient continues our biomarkers Cyteir to the action the team improve execute clinical As on the program,
We expect cohorts X CYT-XXXX data of from stage the and the completion first on the monotherapy Phase a data X Phase cohort. the safety of combination
Gaiero that, and the over considerable to to in We you like progress Dave fourth progress Dave? have the year. the throughout review forward already to quarter call our updating on made to turn financials. ‘XX look With I’d
